Compare AbCellera Biologics Inc (ABCL) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Monolithic Power Systems Inc — how do they compare? AbCellera Biologics Inc trades at $9.86 (market cap $2.99B), while Monolithic Power Systems Inc trades at $1,448 (market cap $68.90B). The key difference: Monolithic Power Systems Inc is far larger — about 23× AbCellera Biologics Inc's market cap, and Monolithic Power Systems Inc pays a 0.57% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MPWR | |
|---|---|---|
Market Cap | $2.99B | $68.90B |
Sector | Health | Utilities |
52-Week High | $9.76 | $1.69K |
52-Week Low | $2.78 | $820.74 |
Enterprise Value | $2.58B | $67.51B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
MPWR is trading at $1,446.91, up 4.77% in the last 24 hours, with a bullish technical signal and strong earnings momentum after beating Q2 2026 estimates. The stock shows robust fundamentals with a 24.5% net income margin and 21.98% ROE, though valuation ratios like P/E of 85.55 are elevated. Recent news highlights AI-driven revenue growth and a legal investigation into potential misleading statements.
The outlook is positive with an 88% analyst buy rating and a $1,870 consensus price target, but risks include high valuation sensitivity, competitive pressures, and legal scrutiny. Earnings growth from AI infrastructure demand remains a key catalyst for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
